UnitedHealth Group (NYSE:UNH) posted its earnings results on Tuesday. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.91 by $0.13, Bloomberg Earnings reports. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.29%. The business had revenue of $55.19 billion for the quarter, compared to analysts’ expectations of $54.90 billion. During the same period in the prior year, the company posted $2.37 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year.
UNH stock opened at $230.32 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.73 and a current ratio of 0.73. UnitedHealth Group has a 52 week low of $164.96 and a 52 week high of $250.79. The firm has a market cap of $217,027.44, a P/E ratio of 22.25, a price-to-earnings-growth ratio of 1.31 and a beta of 0.77.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 20th. Investors of record on Friday, March 9th were issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend was Thursday, March 8th. UnitedHealth Group’s dividend payout ratio is currently 29.79%.
In related news, Director Kenneth Irwin Shine sold 198 shares of the stock in a transaction on Friday, January 19th. The shares were sold at an average price of $242.55, for a total transaction of $48,024.90. Following the transaction, the director now owns 1,790,567 shares of the company’s stock, valued at approximately $434,302,025.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William C. Ballard, Jr. sold 10,000 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $246.38, for a total transaction of $2,463,800.00. Following the transaction, the director now directly owns 76,637 shares in the company, valued at approximately $18,881,824.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 77,015 shares of company stock worth $17,879,199. 0.89% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Intellectus Partners LLC grew its holdings in shares of UnitedHealth Group by 18.2% during the 2nd quarter. Intellectus Partners LLC now owns 818 shares of the healthcare conglomerate’s stock valued at $152,000 after purchasing an additional 126 shares during the last quarter. Sunbelt Securities Inc. purchased a new stake in UnitedHealth Group during the 2nd quarter valued at $218,000. M&R Capital Management Inc. boosted its position in UnitedHealth Group by 14.8% during the 2nd quarter. M&R Capital Management Inc. now owns 1,550 shares of the healthcare conglomerate’s stock valued at $299,000 after buying an additional 200 shares during the period. Coldstream Capital Management Inc. boosted its position in UnitedHealth Group by 37.8% during the 2nd quarter. Coldstream Capital Management Inc. now owns 1,698 shares of the healthcare conglomerate’s stock valued at $315,000 after buying an additional 466 shares during the period. Finally, Highland Private Wealth Management boosted its position in UnitedHealth Group by 0.4% during the 2nd quarter. Highland Private Wealth Management now owns 3,199 shares of the healthcare conglomerate’s stock valued at $593,000 after buying an additional 13 shares during the period. 86.78% of the stock is currently owned by institutional investors.
UNH has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $240.00 target price on the stock in a research note on Tuesday, April 3rd. Deutsche Bank increased their target price on shares of UnitedHealth Group to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald reiterated a “buy” rating and issued a $235.00 target price on shares of UnitedHealth Group in a research note on Tuesday, January 16th. BMO Capital Markets increased their target price on shares of UnitedHealth Group from $14.50 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 17th. Finally, Credit Suisse Group increased their target price on shares of UnitedHealth Group from $252.00 to $260.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $244.62.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.